CA
PHVS icon

Centerpoint Advisors’s Pharvaris PHVS Stock Holding History

Centerpoint Advisors’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
100
– – ﹤0.01% 375
2026
Q1 		$3K Hold
100
– – ﹤0.01% 361
2025
Q4 		$3K Hold
100
– – ﹤0.01% 372
2025
Q3 		$2K Hold
100
– – ﹤0.01% 409
2025
Q2 		$2K Buy
+100
New +$1.61K ﹤0.01% 352

Other funds holding PHVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
OCA
OpenArc Corporate Advisory Atlanta, Georgia $8.41B AUM

Centerpoint Advisors's PHVS Position: Q2 2026 in Review

Centerpoint Advisors held its Pharvaris (PHVS) position steady in Q2 2026 at 100 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #375.

Centerpoint Advisors first reported a position in PHVS in Q2 2025 and has held it in 5 quarters since. 23 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

  • Centerpoint Advisors held 100 shares of Pharvaris worth $3K as of Q2 2026.
  • Centerpoint Advisors left its Pharvaris share count unchanged in Q2 2026.
  • Pharvaris made up ﹤0.01% of Centerpoint Advisors's portfolio in Q2 2026, its #375 holding.
  • Centerpoint Advisors first reported a position in Pharvaris in Q2 2025 and has held it in 5 quarters since.
  • 23 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.